Literature DB >> 23750660

The feasibility of pharmacy-based naloxone distribution interventions: a qualitative study with injection drug users and pharmacy staff in Rhode Island.

Nickolas D Zaller1, Michael A Yokell, Traci Craig Green, Julia Gaggin, Patricia Case.   

Abstract

This study analyzed qualitative data from a Rapid Policy Assessment and Response project to assess the feasibility of a potential pharmacy-based naloxone intervention to reduce opioid overdose mortality among injection drug users (IDUs). We conducted in-depth, semistructured interviews with 21 IDUs and 21 pharmacy staff (pharmacists and technicians). Although most participants supported the idea of a pharmacy-based naloxone intervention, several barriers were identified, including misinformation about naloxone, interpersonal relationships between IDUs and pharmacy staff, and costs of such an intervention. Implications for future pharmacy-based overdose prevention interventions for IDUs, including pharmacy-based naloxone distribution, are considered. The study's limitations are noted.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23750660     DOI: 10.3109/10826084.2013.793355

Source DB:  PubMed          Journal:  Subst Use Misuse        ISSN: 1082-6084            Impact factor:   2.164


  14 in total

Review 1.  Harm reduction for young people who use prescription opioids extra-medically: Obstacles and opportunities.

Authors:  Brandon D L Marshall; Traci C Green; Jesse L Yedinak; Scott E Hadland
Journal:  Int J Drug Policy       Date:  2016-02-04

2.  Opioid overdose prevention through pharmacy-based naloxone prescription program: Innovations in health care delivery.

Authors:  Amy Bachyrycz; Shikhar Shrestha; Barry E Bleske; Dale Tinker; Ludmila N Bakhireva
Journal:  Subst Abus       Date:  2016-05-10       Impact factor: 3.716

3.  Nonprescription naloxone and syringe sales in the midst of opioid overdose and hepatitis C virus epidemics: Massachusetts, 2015.

Authors:  Thomas J Stopka; Ashley Donahue; Marguerite Hutcheson; Traci C Green
Journal:  J Am Pharm Assoc (2003)       Date:  2017-02-08

4.  Moving beyond misuse and diversion: the urgent need to consider the role of iatrogenic addiction in the current opioid epidemic.

Authors:  Gillian A Beauchamp; Erin L Winstanley; Shawn A Ryan; Michael S Lyons
Journal:  Am J Public Health       Date:  2014-09-11       Impact factor: 9.308

5.  Prescribers and Naloxone Pharmacy Claims.

Authors:  Rosanna Smart; Caroline K Geiger; Christopher M Jones; Bradley D Stein
Journal:  J Gen Intern Med       Date:  2020-08       Impact factor: 5.128

6.  Evaluation of naloxone furnishing community pharmacies in San Francisco.

Authors:  Andy M Nguyen; Thomas E Kearney; Dorie E Apollonio
Journal:  J Am Pharm Assoc (2003)       Date:  2020-09-15

7.  Legal requirements and recommendations to prescribe naloxone.

Authors:  Rebecca L Haffajee; Samantha Cherney; Rosanna Smart
Journal:  Drug Alcohol Depend       Date:  2020-02-06       Impact factor: 4.492

8.  Neighborhood-Level and Spatial Characteristics Associated with Lay Naloxone Reversal Events and Opioid Overdose Deaths.

Authors:  Christopher Rowe; Glenn-Milo Santos; Eric Vittinghoff; Eliza Wheeler; Peter Davidson; Philip O Coffin
Journal:  J Urban Health       Date:  2016-02       Impact factor: 3.671

9.  Alternate Routes of Administration among Prescription Opioid Misusers and Associations with Sexual HIV Transmission Risk Behaviors.

Authors:  Mance E Buttram; Steven P Kurtz
Journal:  J Psychoactive Drugs       Date:  2016-05-25

10.  Assessing pharmacy-based naloxone access using an innovative purchase trial methodology.

Authors:  Robin A Pollini; Rebecca Joyce; Jenny E Ozga-Hess; Ziming Xuan; Traci C Green; Alexander Y Walley
Journal:  J Am Pharm Assoc (2003)       Date:  2020-07-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.